Your browser doesn't support javascript.
loading
Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal.
Toumi, Mondher; Dabbous, Omar; Aballéa, Samuel; Drummond, Michael F; von der Schulenburg, Johann-Matthias Graf; Malone, Daniel C; Neumann, Peter J; Sullivan, Sean D; Tunis, Sean.
Affiliation
  • Toumi M; Laboratoire de Santé Publique, Aix-Marseille Université, Public Health Department, Marseille, France.
  • Dabbous O; Global Geneconomics and Outcomes Research, Novartis Gene Therapies, Inc, Bannockburn, IL, USA.
  • Aballéa S; Creativ-Ceutical, Paris, France.
  • Drummond MF; Centre for Health Economics, University of York, York, UK.
  • von der Schulenburg JG; Institute for Risk and Insurance, Leibniz Universtät Hannover, Hanover, Germany.
  • Malone DC; Department of Pharmacotherapy, University of Utah, Salt Lake City, UT, USA.
  • Neumann PJ; Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
  • Sullivan SD; CHOICE Institute, University of Washington, Seattle, WA, USA.
  • Tunis S; Rubix Health, Baltimore, MD, USA.
Expert Rev Pharmacoecon Outcomes Res ; 23(5): 483-497, 2023 Jun.
Article in En | MEDLINE | ID: mdl-37074838
ABSTRACT

OBJECTIVE:

No consensus exists on the ideal methodology to evaluate the economic impact and value of new, potentially curative gene therapies. We aimed to identify and describe published methodologic recommendations for the economic evaluation of gene therapies and assess whether these recommendations have been applied in published evaluations.

METHODS:

This study was conducted in three stages a systematic literature review of methodologic recommendations for economic evaluation of gene therapies; an assessment of the appropriateness of recommendations; and a review to assess the degree to which the recommendations were applied in published evaluations.

RESULTS:

A total of 2,888 references were screened, 83 articles were reviewed to assess eligibility, and 20 papers were included. Fifty recommendations were identified, and 21 reached consensus thresholds. Most evaluations were based on naive treatment comparisons and did not apply consensus recommendations. Innovative payment mechanisms for gene therapies were rarely considered. The only widely applied recommendations related to modeling choices and methods.

CONCLUSIONS:

Methodological recommendations for economic evaluations of gene therapies are generally not being followed. Assessing the applicability and impact of the recommendations from this study may facilitate the implementation of consensus recommendations in future evaluations.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genetic Therapy Type of study: Guideline / Health_economic_evaluation / Health_technology_assessment / Systematic_reviews Aspects: Patient_preference Limits: Humans Language: En Journal: Expert Rev Pharmacoecon Outcomes Res Journal subject: FARMACOLOGIA Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genetic Therapy Type of study: Guideline / Health_economic_evaluation / Health_technology_assessment / Systematic_reviews Aspects: Patient_preference Limits: Humans Language: En Journal: Expert Rev Pharmacoecon Outcomes Res Journal subject: FARMACOLOGIA Year: 2023 Document type: Article Affiliation country:
...